Approach to identifying and managing atherogenic dyslipidemia: A metabolic consequence of obesity and diabetes

Canadian Family Physician

Volumn 59, Issue 11, 2013, Pages

  Bosomworth, N John ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; APOLIPOPROTEIN B; ATORVASTATIN; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL OBESITY; ADULT; ALCOHOL CONSUMPTION; ATHEROGENIC DYSLIPIDEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DECISION SUPPORT SYSTEM; DEMENTIA; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG TOLERABILITY; DYSLIPIDEMIA; FAMILY HISTORY; FRAMINGHAM RISK SCORE; GLUCOSE INTOLERANCE; GRAPEFRUIT JUICE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; KIDNEY FAILURE; LIVER FAILURE; LIVER INJURY; MALE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MYALGIA; MYOPATHY; NUMBERS NEEDED TO TREAT; OBESITY; POSTOPERATIVE DELIRIUM; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; WAIST CIRCUMFERENCE;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; GLUCOSE INTOLERANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; METABOLIC SYNDROME X; OBESITY; TRIGLYCERIDES;

EID: 84888618993     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Grundy SM. Small LDL, atherogenic dyslipidemia and the metabolic syndrome. Circulation 1997;95(1):1-4.
2. Assmann G, Cullen P, Schulte H. Non-LDL-related dyslipidaemia and coronary risk: a case control study. Diab Vasc Dis Res 2010;7(3):204-12.
3. Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification. J Am Coll Cardiol 2011;58(5):457-63.
4. Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Chapman MJ, et al. The residual risk initiative: a call to action to reduce vascular risk in dyslipidaemic patients. Diab Vasc Dis Res 2008;5(4):319-35.
5. Taslim S, Tai ES. The relevance of metabolic syndrome. Ann Acad Med Singapore 2009;38(1):29-5.
6. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009;25(10):567-79.
7. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GBJ, McPherson R, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29(2):151-67.
8. Hunink MG, Goldman L, Tosteson AN, Mittleman MA, Goldman PA, Williams LW, et al. The recent decline in mortality from coronary heart disease 1980-1990: the effect of secular trends in risk factors and treatment. JAMA 1997;277(7):535-42. (Pubitemid 27083982)
9. Ford ES, Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. J Am Coll Cardiol 2007;50(22):2128-32. (Pubitemid 350117339)
10. Allender S, Scarborough P, O'Flaherty M, Capewell S. Patterns of coronary heart disease over the 20th century in England and Wales: possible plateaus in the rate of decline. BMC Public Health 2008;8:141. Available from: www.biomedcentral.com/1471-2458/8/148. Accessed 2012 Dec 19.
11. O'Flaherty M, Allender S, Taylor R, Stevenson C, Peeters A, Capewell S. The decline in coronary heart disease is slowing in young adults (Australia 1976-2006): a time trend analysis. Int J Cardiol 2012;158(2):193-8.
12. Greenland P. Time to end the mixed - and often incorrect - messages about prevention and treatment of atherosclerotic cardiovascular disease. J Am Coll Cardiol 2007;50(22):2133-5.
13. Orpana HM, Tremblay MS, Fines P. Trends in weight change among Canadian adults: evidence from the 1996/1997 to 2004/2005 National Population Health Survey. Ottawa, ON: Statistics Canada; 2006. Available from: www.statcan.gc.ca/pub/82-618-m/82-618-m2006005-eng.htm. Accessed 2011 Nov 3.
14. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the U.S. J Diabetes 2010;2(3):180-93.
15. Reidiger ND. Prevalence of metabolic syndrome in the Canadian adult population. CMAJ 2011;183(15):e1127-34. Available from: www.ecmaj.ca/content/ early/2011/09/12/cmaj.110070.full.pdf+html. Accessed 2012 Nov 16.
16. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006;119(10):812-9. (Pubitemid 44415613)
17. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome. Circulation 2009;120(16):1640-5.
18. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2004;364(9438):937-52. (Pubitemid 39208455)
19. Marma AK, Berry JD, Ning H, Persell SD, Lloyd-Jones D. Distribution of 10-year and lifetime predicted risks for cardiovascular disease in U.S. adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006. Circ Cardiovasc Qual Outcomes 2010;3(1):8-14.
20. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195-207.
21. Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther 2011;5:325-80.
22. Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D'Agostino RB, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004;94(1):20-4. (Pubitemid 38813447)
23. Yan LL, Daviglus ML, Liu K, Stamler J, Wang R, Pirzada A, et al. Midlife body mass index and hospitalization and mortality in older age. JAMA 2006;295(2):190-8. (Pubitemid 43076438)
24. Lloyd-Jones DM, Dyer AR, Wang R, Daviglus ML, Greenland P. Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death (Chicago Heart Association Detection Project in Industry). Am J Cardiol 2007;99(4):535-40. (Pubitemid 46215561)
25. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012;366(4):321-9.
26. Cameron A. The metabolic syndrome: validity and utility of clinical definitions for cardiovascular disease and diabetes risk prediction. Maturitas 2010;65(2):117-21.
27. Sundström J, Risérus U, Byberg L, Zethelius B, Lithell H, Lind L, et al. Clinical value of the metabolic syndrome for the long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006;332(7546):878-82.
28. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Pasternak RC, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227-39. (Pubitemid 38924592)
29. Reiner Ž, Catapano AL, De Baker G, Graham I, Taskinen MR, Wiklund O, et al. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32(14):1769-818.
30. Sacks FM, Tonkin AM, Craven T, Pfeffer MA, Shepherd J, Keech A, et al. Coronary heart disease with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002;105(12):1424-8. (Pubitemid 34263272)
31. Sniderman A, Williams K, de Graaf J. Non-HDL C equals apolipoprotein B: except when it does not! Curr Opin Lipidol 2010;21(6):518-24.
32. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM, et al. Non-highdensity lipoprotein and very-high density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 2006;98(10):1363-8. (Pubitemid 44666646)
33. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk. J Am Coll Cardiol 2010;56(14):1113-32.
34. Hodis HN. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation 1999;99(22):2852-4. (Pubitemid 29258969)
35. Gardner CD, Fortmann SP, Kraus RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276(11):875-81. (Pubitemid 26301606)
36. Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceriderich lipoprotein metabolism. Circulation 2002;106(16):2137-42. (Pubitemid 35192822)
37. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherogenesis. Circulation 2004;109(Suppl III):III-2-7.
38. Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, et al. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem 2009;55(3):473-80.
39. Brewer HB. The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab 2011;96(5):1246-57.
40. Arsenault BJ, Pibarot P, Després JP. The quest for the optimal assessment of global cardiovascular risk: are traditional risk factors and metabolic syndrome partners in crime? Cardiology 2009;113(1):35-49.
41. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev 2008;29(7):777-822.
42. Chapman MJ, Ginsberg HN, Amarenco P, Anderotti F, Borén J, Catapano AL, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32(11):1345-61.
43. Tenenbaum A, Fisman EZ. "The metabolic syndrome is dead"; these reports are an exaggeration. Cardiovasc Diabetol 2011;10(1):11.
44. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB, et al. Non-highdensity lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005;112(22):3375-83. (Pubitemid 43739551)
45. Jacobson TA. Opening a new lipid "apo-thecary"; incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. Mayo Clin Proc 2011;86(8):762-80.
46. Sniderman AD, Bergeron J, Frohlich J. Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial. CMAJ 2001;164(1):44-7. (Pubitemid 32094884)
47. Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of effectiveness of lowering apolipoproteins B versus low density lipoprotein cholesterol and nonhigh- density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol 2012;110(10):1468-76.
48. Saenger A. Cardiovascular risk assessment beyond LDL cholesterol: non-HDL cholesterol, LDL particle number and apolipoprotein B. Mayo Clinic Communiqué 2011;36(6):1-9.
49. Maki KC, Davidson MH, Dicklin MR. A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-technology (NEPTUNE) II survey. Can J Cardiol 2006;22(4):315-22.
50. Henkin Y. Re-evaluating therapeutic target goals for statin-treated patients: time for revolutionary changes? J Am Coll Cardiol 2008;52(8):633-5.
51. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol apolipoproteins A1 and B100, standard lipid measures, lipid ratios and CRP as risk factors for cardiovascular disease in women. JAMA 2005;294(3):226-333.
52. Hoenig MR. Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target. Vasc Health Risk Manag 2008;4(1):143-56. (Pubitemid 351460855)
53. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins. JAMA 2012;12(12):1302-9.
54. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302(18):1993-2000.
55. Ridker PM. What works and in whom? A simple, easily applied, evidencebased approach to guidelines for statin therapy. Circ Cardiovasc Qual Outcomes 2012;5(4):592-3.
56. Simes RJ, Marschner RC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002;105(10):1162-9. (Pubitemid 34225815)
57. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a metaanalysis of individual data from 61 prospective studies with 55,000 vascular deaths. Prospective Studies Collaboration. Lancet 2007;370(9602):1829-39.
58. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol and coronary heart disease risk. J Am Coll Cardiol 2009;53(4):316-22.
59. Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101(5):477-84. (Pubitemid 30080860)
60. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-60. (Pubitemid 28191300)
61. Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, et al. IDEAL Study Group. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008;117(23):3002-9.
62. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, deGraaf J, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011;4(15):337-45.
63. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. (Pubitemid 351632017)
64. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994;121(9):641-7.
65. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007;298(7):776-85. (Pubitemid 47263160)
66. Holman RR, Shine BS, Coleman RL, Stevens RJ. Non-HDL cholesterol is less informative than total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes. Diabetes Care 2005;28(7):1796-7. (Pubitemid 40923097)
67. Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, et al. Total cholesterol/HDL cholesterol ratio vs. LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease in men: the Quebec Cardiovascular Study. Arch Intern Med 2001;161(22):2685-92. (Pubitemid 33134844)
68. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomized trials. Lancet 2012;380(9841):581-90.
69. Radcliffe KA, Campbell WW. Statin myopathy. Curr Neurol Neurosci Rep 2008;8(1):66-72. (Pubitemid 351166414)
70. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010;41(2):185-90.
71. Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89(12):1374-80. (Pubitemid 34607777)
72. Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105(12):1446-52. (Pubitemid 34263276)
73. Blanco M, Nombela F, Castellanos M, Rodriguez-Yáñez M, García-Gil M, Leira R, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007;69(9):904-10. (Pubitemid 47329591)
74. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative metaanalysis of randomised statin trials. Lancet 2010;375(9716):735-42.
75. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a metaanalysis. JAMA 2011;305(24):2556-64.
76. Mascitelli L, Pezzetta F. Physical activity in statin-treated patients. Int J Cardiol 2009;134(1):136-7.
77. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton Jr. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997;46(10):1206-10. (Pubitemid 27418513)
78. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 2005;25(12):2560-6. (Pubitemid 43732279)
79. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013;346:f880.
80. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197.
81. Rubenfire M, Brook RD, Rosenson RS. Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Am J Med 2010;123(10):892-8.
82. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomized trials of statins. Lancet 2005;366(9493):1267-78.
83. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet 2010;376(9753):1670-81.
84. Mora S, Wenger NK, DeMicco DA, Breazna A, Boekholdt M. Determinants of residual risk in secondary prevention patients treated with high versus low-dose statin therapy: The Treating to New Targets (TNT) study. Circulation 2012;125(16):1979-87.
85. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008;51(7):724-30. (Pubitemid 351221217)
86. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo controlled trial. Lancet 2003;361(9374):2005-16.
87. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 2008;178(5):576-84. (Pubitemid 351414005)
88. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48(3):438-45. (Pubitemid 44109954)
89. Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166(17):1814-21. (Pubitemid 44455162)
90. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomized controlled trials. Heart 2007;93(8):914-21. (Pubitemid 47122038)
91. Mills EJ, O'Regan C, Eyawo O, Wu P, Mills F, Berwanger O, et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of > 40,000 patients. Eur Heart J 2011;32(11):1409-15.
92. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006;368(9539):919-28. (Pubitemid 44331360)
93. Pyörälä K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome. Diabetes Care 2004;27(7):1735-40.
94. Athyros VG, Mikhailidis DP, Liberopaulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Nephrol Dial Transplant 2007;22(1):118-27. (Pubitemid 46050336)
95. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly D, Haffner SN, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108(4):414-9. (Pubitemid 36935533)
96. Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome. Diabetes Care 2005;28(10):2508-13.
97. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes 2012;5(1):2-5.
98. Shepherd J. Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs. Lancet 2002;359(9225):2271-3. (Pubitemid 34717986)
99. Allan GM, Mannarino M. Tools for Practice. How does high dose statin compare to low dose in people with heart disease? Edmonton AB: Alberta College of Family Physicians; 2012. Available from: www.acfp.ca/Portals/0/docs/TFP/ 20120522-090852.pdf. Accessed 2012 Nov 7.
100. Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol 2011;57(2):267-72.
101. Lee M, Saver JL, Towfighi A, Chow J, Ovbiageli B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a metaanalysis. Atherosclerosis 2011;217(2):492-8.
102. Tenenbaum A, Medvedovsky D, Fisman EZ, Bubyr L, Matetzky S, Tanne D, et al. Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: acute coronary syndrome Israeli surveys data. PLoS ONE 2012;7(4):e35298-7.
103. Accord Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1562-74.
104. Jacobson TA, Zimmerman FH. Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens (Greenwich) 2006;8(1):35-41.
105. Guo J, Menq F, Ma N, Li C, Ding Z, Wang H, et al. Meta-analysis of safety of co-administration of statin with fenofibrate in patients with combined hyperlipidemia. Am J Cardiol 2012;110(9):1296-301.
106. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8(6):1245-55. (Pubitemid 17208898)
107. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345(22):1583-92. (Pubitemid 33126837)
108. AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365(24):2255-67.
109. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010;210(2):353-61.
110. Duggal JK, Singh M, Attri N, Singh PP, Ahmed N, Pahwa S, et al. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J Cardiovasc Pharmacol Ther 2010;15(2):158-66.
111. Tenkanen L, Mänttäri M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation 1995;92(7):1779-85.
112. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the benzafibrate infarction prevention (BIP) study. Circulation 2000;102(1):21-7.
113. Rubins HB, Robins SJ, Collins D, Frye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341(6):410-8. (Pubitemid 29362514)
114. Hermans MP. Impact of fenofibrate on type 2 diabetes patients with features of the metabolic syndrome: subgroup analysis from FIELD. Curr Cardiol Rev 2010;6(2):112-8.
115. Kwak SM, Myung SK, Lee YJ, Seo HG. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebocontrolled trials. Arch Intern Med 2012;172(9):686-94.
116. Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr 2012;107(Suppl 2):S201-13.
117. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308(10):1024- 33.
118. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251(3):365-74.
119. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999;19(2):187-95. (Pubitemid 29072729)
120. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis. Lancet 2010;376(9756):1916-22.
121. Allan MG, Zarnke KB. Tools for Practice. Ezetimibe: lowers LDL cholesterol, but what else? Edmonton AB: Alberta College of Family Physicians; 2010. Available from: www.acfp.ca/Portals/0/docs/TFP/20111028-105411.pdf. Accessed 2012 Jul 11.
122. Briel M, Ferreira-Gonzales I, You JJ, Karanikolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and metaregression analysis. BMJ 2009;338:b92.
123. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013;368(14):1279-90.